Table 1.
Baseline demographics and clinical characteristics of patients in training cohort and validation cohort.
| Variables | Training cohort(n = 306) | Validation cohort(n = 132) | P |
|---|---|---|---|
| Age (years) | 56.2 ± 11.4 | 55.9 ± 11.0 | 0.751 |
| Body mass index (Kg/m2) | 22.4 (20.6, 24.5) | 23.0 (20.9,24.5) | 0.249 |
| Tumor size (cm) | 4.0 (3.0,6.0) | 4.0 (3.0,5.0) | 0.561 |
| Prothrombin time activity(s) | 13.3 (12.7, 13.9) | 13.20 (12.60,13.83) | 0.399 |
| APTT(s) | 36.90 (34.32,40.2) | 36.40 (34.0,40.3) | 0.291 |
| ALT | 45 (19,203) | 39 (18,140.5) | 0.177 |
| AST | 36 (18, 95) | 42 (19,133.25) | 0.135 |
| GGT | 75 (20.0,420.0) | 86.5 (20.0, 573.5) | 0.200 |
| CEA (g/L) | 3.0 (1.6,5.65) | 3.85 (2.1, 7.12) | 0.986 |
| CA199 (μmol/L) | 74 (10, 717.02) | 136.9 (19, 1019.75) | 0.236 |
| AFP (mmol/l) | 2.80 (2.0, 4.0) | 2.98 (2.35, 4.03) | 0.301 |
| Gender | 0.836 | ||
| Male | 170 (55.56%) | 92 (69.70%) | |
| Female | 136 (44.44%) | 40 (30.30%) | |
| T stage | 0.001 | ||
| T1 | 20 (6.54%) | 13 (9.85%) | |
| T2 | 143 (46.73%) | 35 (26.52%) | |
| T3 | 126 (41.18%) | 71 (53.79%) | |
| T4 | 17 (5.56%) | 13 (9.85%) | |
| N stage | 0.004 | ||
| N0 | 209 (68.30%) | 71 (53.79%) | |
| N1-3 | 97 (31.70%) | 61 (46.21%) | |
| M stage | 0.011 | ||
| M0 | 266 (86.93%) | 102 (77.27%) | |
| M1 | 40 (13.07%) | 30 (22.73%) | |
| Nerve invasion | 0.014 | ||
| Yes | 248 (81.05%) | 93 (70.45%) | |
| No | 58 (18.95%) | 39 (29.55%) | |
| Vascular invasion | 0.067 | ||
| Yes | 230 (75.16%) | 88 (66.67%) | |
| No | 76 (24.84%) | 44 (33.33%) |
BMI, Body mass index; AFP, Alpha-fetoprotein; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; GGT, γ-glutamyl transpeptidase.